In our laboratory, in vivo experiments with APPswePS1dE9 transgenic mouse model have been performed to determine if this specific PKR inhibitor could be relevant in the treatment of AD (data submitted). The gene discussed is EIF2AK2; the disease is Alzheimer disease.